Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics presented updated preclinical data at ESMO 2026 showing PIKTOR inhibited tumor growth in HR+/HER2- breast cancer xenografts to a comparable or greater extent than intravenous gedatolisib, billed as the first-ever head-to-head characterization of the two multi-node PAM inhibitors. In combination with fulvestrant and palbociclib, PIKTOR achieved complete tumor growth inhibition or regression, and in kinase assays it reduced AKT activity to roughly 10% of uninhibited levels, deeper than single-node inhibitors tested.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.